Sotera Health Co
$ 15.76
0.38%
04 Mar - close price
- Market Cap 4,482,019,000 USD
- Current Price $ 15.76
- High / Low $ 15.89 / 15.61
- Stock P/E 58.37
- Book Value 2.13
- EPS 0.27
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 19.85
- 52 Week Low 9.53
About
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Analyst Target Price
$20.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-04 | 2025-08-08 | 2025-04-30 | 2025-02-25 | 2024-11-05 | 2024-08-05 | 2024-05-02 | 2024-02-27 | 2023-11-01 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.26 | 0.26 | 0.2 | 0.14 | 0.21 | 0.17 | 0.19 | 0.13 | 0.26 | 0.21 | 0.21 | 0.13 |
| Estimated EPS | 0.2422 | 0.2167 | 0.17 | 0.1218 | 0.2019 | 0.18 | 0.16 | 0.13 | 0.26 | 0.2 | 0.18 | 0.14 |
| Surprise | 0.0178 | 0.0433 | 0.03 | 0.0182 | 0.0081 | -0.01 | 0.03 | 0 | 0 | 0.01 | 0.03 | -0.01 |
| Surprise Percentage | 7.3493% | 19.9815% | 17.6471% | 14.9425% | 4.0119% | -5.5556% | 18.75% | 0% | 0% | 5% | 16.6667% | -7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.1744 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SHC
2026-03-05 00:52:29
Sotera Health (SHC) held its Q4 earnings call, reporting steady growth, margin expansion, and strong cash generation for 2025 with $1.164 billion in revenue and adjusted EBITDA climbing to $593.8 million. The company provided 2026 guidance expecting continued revenue growth between $1.233 billion and $1.251 billion and adjusted EBITDA of $632 million to $641 million, demonstrating confidence despite segment-specific challenges and ongoing litigation. Management highlighted operational wins, improved governance, and significant liquidity, positioning the company for long-term compounding growth.
2026-03-04 21:52:29
Sotera Health Co. has filed a Form 424B7 prospectus supplement for the sale of common stock by existing selling stockholders. The company will not receive any proceeds from this offering, and the stock is listed on Nasdaq under "SHC." The document details financial data, risk factors, and information about shareholder ownership and governance, including the decreasing influence of Warburg Pincus and GTCR.
2026-03-04 21:52:29
Sotera Health Company (Nasdaq: SHC) announced a secondary offering of 25 million shares of its common stock. The shares are being sold by affiliates of Warburg Pincus LLC and GTCR LLC, and Sotera Health will not receive any proceeds from the offering. Wells Fargo Securities is acting as the underwriter.
2026-03-04 17:52:29
This page provides access to Sotera Health Co (SHC) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms. It details recent filings such as secondary offerings by Warburg Pincus and GTCR, a prospectus outlining financial data and risks, and a Q2 2025 earnings report. The company operates in mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry.
2026-03-04 02:51:32
Sotera Health Company (SHC), a key player in the healthcare diagnostics and research industry, shows a potential upside of 30% from its current stock price, with an average target price of $20.75. The company's strong financial health is supported by $4.52 billion market cap, 4.60% revenue growth, and $237 million in free cash flow, along with favorable analyst ratings. Despite not offering dividends, its innovative sterilization and testing solutions through segments like Sterigenics, Nordion, and Nelson Labs position it for continued growth in the medical device, pharmaceutical, and food safety sectors.
2026-03-03 15:40:00
Sotera Health (SHC) has seen a 13% drop in its share price over the past month but shows signs of a potential rebound. Its Relative Strength Index (RSI) of 28.73 indicates the stock is oversold, suggesting selling pressure may be easing. Analysts have also raised earnings forecasts and the company holds a Zacks Rank #2 (Buy), pointing towards a near-term turnaround.
